These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 30535947)

  • 1. Targeted Therapies in CLL: Monotherapy Versus Combination Approaches.
    Khan M; Siddiqi T
    Curr Hematol Malig Rep; 2018 Dec; 13(6):525-533. PubMed ID: 30535947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
    Hillmen P; Rawstron AC; Brock K; Muñoz-Vicente S; Yates FJ; Bishop R; Boucher R; MacDonald D; Fegan C; McCaig A; Schuh A; Pettitt A; Gribben JG; Patten PEM; Devereux S; Bloor A; Fox CP; Forconi F; Munir T
    J Clin Oncol; 2019 Oct; 37(30):2722-2729. PubMed ID: 31295041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
    Jain N; O'Brien S
    Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
    Odetola O; Ma S
    Curr Hematol Malig Rep; 2023 Oct; 18(5):130-143. PubMed ID: 37278884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What Is the Role of Chemotherapy in Patients With Chronic Lymphocytic Leukemia?
    Cheson BD
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):723-727. PubMed ID: 28780145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
    Hallek M
    Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options.
    Jain N; Thompson P; Ferrajoli A; Nabhan C; Mato AR; O'Brien S
    Am Soc Clin Oncol Educ Book; 2018 May; 38():580-591. PubMed ID: 30231393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
    Shah A; Mangaonkar A
    Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Barrientos JC
    Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax alone or in combination with other regimens treatment achieve deep and sustained remission of relapsed/refractory chronic lymphocytic leukemia: a meta-analysis.
    Tang X; Zou W; Peng P; Bai Y
    Clin Exp Med; 2022 May; 22(2):161-171. PubMed ID: 34224006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.
    Bachow SH; Lamanna N
    Curr Hematol Malig Rep; 2016 Feb; 11(1):61-70. PubMed ID: 26951237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.
    Aw A; Brown JR
    Leuk Lymphoma; 2017 Oct; 58(10):2287-2297. PubMed ID: 28482721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promising therapies for the treatment of chronic lymphocytic leukemia.
    Morabito F; Recchia AG; Vigna E; De Stefano L; Bossio S; Morabito L; Pellicanò M; Palummo A; Storino F; Caruso N; Gentile M
    Expert Opin Investig Drugs; 2015 Jun; 24(6):795-807. PubMed ID: 25728009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections.
    Hilal T; Gea-Banacloche JC; Leis JF
    Blood Rev; 2018 Sep; 32(5):387-399. PubMed ID: 29571669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolving treatment landscape of chronic lymphocytic leukemia.
    Schiattone L; Ghia P; Scarfò L
    Curr Opin Oncol; 2019 Nov; 31(6):568-573. PubMed ID: 31593975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review.
    Thompson M; Brander D; Nabhan C; Mato A
    JAMA Oncol; 2018 Mar; 4(3):394-400. PubMed ID: 28750119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.
    Abou Zahr A; Bose P; Keating MJ
    Expert Opin Pharmacother; 2017 Jun; 18(9):857-873. PubMed ID: 28446054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs.
    Smolewski P; Robak T
    Acta Haematol; 2021; 144(4):365-379. PubMed ID: 33238270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frontline Therapy of Chronic Lymphocytic Leukemia: Changing Treatment Paradigm.
    Sengar M; Jain H; Rajendra A; Rengaraj K; Thorat J
    Curr Hematol Malig Rep; 2020 Jun; 15(3):168-176. PubMed ID: 32542586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.